{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007913","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2025-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.690425+00:00","generated_at":"2026-05-16T13:21:02.527548+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edesa reports FY2025 net loss $7.2M; Phase 3 paridiprubart meets endpoints","bullets":["Net loss $7.2M ($1.27/share) vs $6.2M ($1.93/share) prior year; OpEx $7.9M.","Cash $10.8M at Sept 30, 2025; raised $3.4M net from ATM post-year-end.","Phase 3 paridiprubart met primary/secondary endpoints; exploring partnerships.","Initiated manufacturing for Phase 2 EB06 vitiligo study; recruitment mid-2026.","Canadian gov't funding extended for respiratory program; JP Morgan meetings planned Jan 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007913","json":"https://secwatch.observer/filing/0001171843-25-007913.json","markdown":"https://secwatch.observer/filing/0001171843-25-007913.md","text":"https://secwatch.observer/filing/0001171843-25-007913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/0001171843-25-007913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325007913/f8k_121125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:21:02.527548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}